Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/topical-imiquimod-or-fluorouracil-therapy-for-basal-and-squamous-cell-AplOKqo9Gj
References (48)
-
H. Bargman, J. Hochman (2003)
Topical Treatment of Bowen's Disease with 5-FluorouracilJournal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology, 7
-
G. Patel, R. Goodwin, M. Chawla, P. Laidler, P. Price, A. Finlay, R. Motley (2006)
Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial.Journal of the American Academy of Dermatology, 54 6
-
M. Silverman, A. Kopf, C. Grin, R. Bart, M. Levenstein (1991)
Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation.The Journal of dermatologic surgery and oncology, 17 9
-
Anderson Fe, Johnson Am, Havyatt Mt (1969)
Preliminary studies in the use of 5-fluoro-uracil cream in the treatment of malignant and premalignant skin tumours.The Medical Journal of Australia, 2
-
K. Gross, L. Kircik, G. Kricorian (2007)
5% 5‐Fluorouracil Cream for the Treatment of Small Superficial Basal Cell Carcinoma: Efficacy, Tolerability, Cosmetic Outcome, and Patient SatisfactionDermatologic Surgery, 33
-
A. Huber, J. Huber, R. Skinner, R. Kuwahara, Raashid Haque, R. Amonette (2004)
Topical Imiquimod Treatment for Nodular Basal Cell Carcinomas: An Open‐Label SeriesDermatologic Surgery, 30
-
M. Ebell, J. Siwek, B. Weiss, S. Woolf, J. Susman, B. Ewigman, Marjorie Bowman (2004)
Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature.American family physician, 69 3
-
Dan Rowe, R. Carroll, C. Day (1989)
Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up.The Journal of dermatologic surgery and oncology, 15 3
-
June Robinson, R. Dellavalle, M. Bigby, J. Callen (2008)
Systematic reviews: grading recommendations and evidence quality.Archives of dermatology, 144 1
-
H Stevens, S Choon, H. Hennies, D. Kelsell (1999)
Evidence for a single genetic locus in Clouston's hidrotic ectodermal dysplasiaBritish Journal of Dermatology, 140
-
K. Peris, E. Campione, T. Micantonio, G. Marulli, M. Fargnoli, S. Chimenti (2005)
Imiquimod Treatment of Superficial and Nodular Basal Cell Carcinoma: 12‐Week Open‐Label TrialDermatologic Surgery, 31
-
R. Marks, M. Owens, Shelley-Ann Walters (2004)
Efficacy and safety of 5% imiquimod cream in treating patients with multiple superficial basal cell carcinomas.Archives of dermatology, 140 10
-
June Robinson (2004)
Segmental Reconstruction of the FaceDermatologic Surgery, 30
-
I. Mandekou‐Lefaki, F. Delli, T. Koussidou‐Eremondi, O. Mourellou-Tsatsou, Alexander Dionyssopoulos (2005)
Imiquimod 5% cream: a new treatment for Bowen's disease.International journal of tissue reactions, 27 1
-
H. Gollnick, C. Barona, R. Frank, T. Ruzicka, M. Megahed, J. Maus, U. Munzel (2008)
Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe.European journal of dermatology : EJD, 18 6
-
W. Sterry, T. Ruzicka, E. Herrera, A. Takwale, J. Bichel, K. Andres, L. Ding, M. Thissen (2002)
Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low‐frequency dosing with and without occlusionBritish Journal of Dermatology, 147
-
T. Eigentler, A. Kamin, B. Weide, H. Breuninger, U. Caroli, M. Möhrle, P. Radny, C. Garbe (2007)
A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma.Journal of the American Academy of Dermatology, 57 4
-
Y. Vun, G. Siller (2006)
Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: A 3‐year retrospective follow‐up studyAustralasian Journal of Dermatology, 47
-
J. Geisse, P. Rich, A. Pandya, K. Gross, K. Andres, A. Ginkel, M. Owens (2002)
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study.Journal of the American Academy of Dermatology, 47 3
-
S. Shumack, K. Gebauer, C. Quirk, K. Macdonald, Shelley-Ann Walters, M. Owens (2004)
5% imiquimod cream for the treatment of large superficial basal cell carcinoma.Archives of dermatology, 140 10
-
C. Schiessl, Carola Wolber, M. Tauber, F. Offner, R. Strohal (2007)
Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up.Journal of drugs in dermatology : JDD, 6 5
-
E. Cowen, M. Mercurio, A. Gaspari (2002)
An open case series of patients with basal cell carcinoma treated with topical 5% imiquimod cream.Journal of the American Academy of Dermatology, 47 4 Suppl
-
Aldara (imiquimod) cream, 5% [package insert]. -
J. Leppälä, K. Kaarniranta, H. Uusitalo, M. Kontkanen (2007)
Imiquimod in the treatment of eyelid basal cell carcinoma.Acta ophthalmologica Scandinavica, 85 5
-
R. Miller, J. Gerster, M. Owens, H. Slade, M. Tomai (1999)
Imiquimod applied topically: a novel immune response modifier and new class of drug.International journal of immunopharmacology, 21 1
-
Efudex (fluorouracil) cream, 5% [package insert]. -
C. Quirk, K. Gebauer, M. Owens, P. Stampone (2006)
Two‐year interim results from a 5‐year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeksAustralasian Journal of Dermatology, 47
-
N. Dubin, A. Kopf (1983)
Multivariate risk score for recurrence of cutaneous basal cell carcinomas.Archives of dermatology, 119 5
-
K. Peris, T. Micantonio, M. Fargnoli, G. Lozzi, S. Chimenti (2006)
Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma.Journal of the American Academy of Dermatology, 55 2
-
H. Sturm (1979)
Bowen's disease and 5-fluorouracil.Journal of the American Academy of Dermatology, 1 6
-
G. Guyatt, D. Gutterman, M. Baumann, D. Addrizzo-Harris, E. Hylek, B. Phillips, G. Raskob, S. Lewis, H. Schünemann (2006)
Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force.Chest, 129 1
-
D. Vidal, X. Matías-Guiu, A. Alomar (2007)
Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up.Archives of dermatology, 143 2
-
L. Bianchi, A. Costanzo, E. Campione, S. Nisticò, S. Chimenti (2003)
Superficial and nodular basal cell carcinomas treated with an immune response modifier: a report of seven patientsClinical and Experimental Dermatology, 28
-
R. Marks, K. Gebauer, S. Shumack, M. Amies, J. Bryden, T. Fox, M. Owens (2001)
Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial.Journal of the American Academy of Dermatology, 44 5
-
C. Morton, M. Horn, J. Leman, B. Tack, C. Bédane, M. Tjioe, S. Ibbotson, A. Khemis, P. Wolf (2006)
Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial.Archives of dermatology, 142 6
-
A. MacKenzie‐Wood, S. Kossard, J. Launey, B. Wilkinson, M. Owens (2001)
Imiquimod 5% cream in the treatment of Bowen's disease.Journal of the American Academy of Dermatology, 44 3
-
A. Salim, J. Leman, J. Leman, J. Mccoll, R. Chapman, C. Morton (2003)
Randomized comparison of photodynamic therapy with topical 5‐fluorouracil in Bowen's diseaseBritish Journal of Dermatology, 148
-
D. Vidal, Xavier Matias-Guiu, A. Alomar (2004)
Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinomaClinical and Experimental Dermatology, 29
-
M. Murphy, D. Brodland, J. Zitelli (2008)
Definitive surgical treatment of 24 skin cancers not cured by prior imiquimod therapy: a case series.Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 34 9
-
Drugstore.com: the uncommon drugstore. -
H. Gollnick, C. Barona, R. Frank, T. Ruzicka, M. Megahed, V. Tebbs, M. Owens, P. Stampone (2005)
Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe.European journal of dermatology : EJD, 15 5
-
S. Shumack, June Robinson, S. Kossard, L. Golitz, H. Greenway, A. Schroeter, K. Andres, M. Amies, M. Owens (2002)
Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.Archives of dermatology, 138 9
-
N Stone, S Burge (1999)
Bowen's disease of the leg treated with weekly pulses of 5% fluorouracil cream., 140
-
J. Neville, Erin Welch, D. Leffell (2007)
Management of nonmelanoma skin cancer in 2007Nature Clinical Practice Oncology, 4
-
H. Hemmi, T. Kaisho, O. Takeuchi, Shintaro Sato, H. Sanjo, K. Hoshino, T. Horiuchi, H. Tomizawa, K. Takeda, S. Akira (2002)
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathwayNature Immunology, 3
-
T. Rosen, Mandy Harting, M. Gibson (2007)
Treatment of Bowen's Disease with Topical 5% Imiquimod Cream: Retrospective StudyDermatologic Surgery, 33
-
H. Schulze, B. Cribier, L. Requena, J. Reifenberger, C. Ferrándiz, A. Diez, V. Tebbs, S. McRae (2005)
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle‐controlled phase III study in EuropeBritish Journal of Dermatology, 152
-
J. Geisse, I. Caro, J. Lindholm, L. Golitz, P. Stampone, M. Owens (2004)
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies.Journal of the American Academy of Dermatology, 50 5
- Publisher
- American Medical Association
- Copyright
- Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
- ISSN
- 2168-6068
- eISSN
- 2168-6084
- DOI
- 10.1001/archdermatol.2009.291
- pmid
- 20026854
- Publisher site
- See Article on Publisher Site
Abstract
EVIDENCE-BASED DERMATOLOGY: REVIEW Topical Imiquimod or Fluorouracil Therapy for Basal and Squamous Cell Carcinoma A Systematic Review W. Elliot Love, DO; Jeffrey D. Bernhard, MD, FRCP(Edin); Jeremy S. Bordeaux, MD, MPH Objectives: To conduct a systematic review to deter- for SCC in situ, and 71% for invasive SCC. Fluorouracil mine clearance rates and adverse effects of topical imi- use produced the following clearance rates: 90% for su- quimod or fluorouracil therapy in the treatment of non- perficial BCC and 27% to 85% for SCC in situ. Up to 100% melanoma skin cancers such as basal (BCC) and squamous and 97% of patients applying imiquimod and fluoroura- cell carcinoma (SCC), and to develop recommenda- cil, respectively, experienced at least 1 adverse event. Ad- tions for the use of topical imiquimod or fluorouracil to verse event intensity ranged from mild to severe; ery- treat BCC and SCC. thema, pruritus, and pain were common. Data Sources: MEDLINE, CANCERLIT, and Coch- Conclusions: Evidence supports the use of topical imi- rane databases. quimod as monotherapy for superficial BCC and topical fluorouracil as monotherapy for superficial BCC and SCC Study Selection: Prospective, retrospective, and case in situ. Based on the available evidence, the strength of
Journal
JAMA Dermatology – American Medical Association
Published: Dec 1, 2009